The Board of Anagenics Limited announced the intention of Mr. Dennis Eck to retire as a director following the completion of the Company's 2022 Annual General Meeting. Mr. Eck made a strategic investment in the company in December 2017 and has been a Non- Executive Director at Anagenics since March 2018. Dennis has been supportive of the continuing restructuring and repositioning of the Business and expresses his intention to continue as a supportive shareholder.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.007 AUD | -12.50% |
|
+16.67% | -63.16% |
24/05 | Anagenics Signs Midkine Antibody Licencing Deal with Roquefort Therapeutics | MT |
08/03 | Anagenics Appoints CEO | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-63.16% | 24.5L | |
+13.86% | 39TCr | |
+16.53% | 14TCr | |
+23.82% | 8.1TCr | |
-8.17% | 6.85TCr | |
-22.13% | 4.08TCr | |
-13.38% | 3.57TCr | |
+4.20% | 3.38TCr | |
+10.88% | 1.85TCr | |
+24.91% | 1.69TCr |
- Stock Market
- Equities
- AN1 Stock
- News Anagenics Limited
- Anagenics Limited Announces Resignation of Dennis Eck as Director